Space Drug-Making Goes Commercial as NASA Charts Nuclear Path to Mars

Breaking: Dual Space Milestones Reshape Industry

Varda Space Industries has inked a landmark deal with pharmaceutical giant United Therapeutics to test whether drugs crystallize differently in microgravity—potentially unlocking superior versions of existing medicines. Separately, NASA confirmed it aims to launch the first nuclear reactor-powered interplanetary spacecraft to Mars by the end of 2028, upping the ante in the global space race.

The twin announcements, made within weeks of each other, signal a decisive shift from theoretical research to commercial and governmental action in orbit. “We’re seeing space transition from a place of exploration to a platform for production,” said Dr. Alice Nakamura, a space industry analyst at the Center for Strategic and International Studies. “These projects could redefine both medicine and deep-space travel.”

Drug Crystals in Microgravity

Under the deal, Varda will fly United Therapeutics’ drug compounds to its orbital manufacturing platform, where they will crystallize in near-zero gravity. The startup believes that removing gravity’s effects could produce crystals with improved purity, solubility, or bioavailability—qualities that are difficult to achieve on Earth.

“This is not science fiction—it’s the next logical step in pharmaceutical engineering,” said Varda CEO Will Bruey in a statement. “Falling launch costs and reusable rockets make space-based manufacturing economically viable for the first time.” The company plans to return the crystallized samples to Earth for analysis within the next 18 months.

Background: The Road to Orbital Manufacturing

For decades, the International Space Station hosted small-scale experiments in microgravity, but high costs kept commercial participation minimal. The rise of private launch providers like SpaceX and Rocket Lab has slashed the price per kilogram to orbit by over 90% since 2010.

Varda’s dedicated orbital factory, a free-flying spacecraft called the W-1, is designed to host multiple drug-crystallization runs simultaneously. The company has already secured a $12 million contract from the U.S. Air Force for materials science research.

NASA’s Nuclear Gamble

While Varda focuses on low Earth orbit, NASA is aiming far deeper. The agency’s Nuclear Thermal Propulsion (NTP) project seeks to build a spacecraft that uses a nuclear reactor to heat propellant, generating thrust far more efficiently than chemical rockets. A successful test flight to Mars by 2028 would cut travel time from nine months to just four.

“The technology is shrouded in secrecy because it involves both propulsion and potential national security applications,” said Dr. Robert Zubrin, author of The Case for Mars. “But if it works, the U.S. gains a decisive edge in the race with China for lunar and Martian resources.” China has announced its own crewed Mars mission target for 2033.

What This Means

For pharmaceuticals, orbital manufacturing could yield blockbuster drugs with fewer side effects or longer shelf lives. United Therapeutics and Varda are specifically targeting treatments for pulmonary hypertension and cancer—conditions where improved drug properties could save thousands of lives annually.

For space exploration, nuclear propulsion transforms Mars from a multi-year round trip into a manageable journey. NASA’s timeline aligns with the Artemis program’s lunar base, which could serve as a testbed for nuclear systems. “We’re looking at a new era where humans are not just visitors to space, but residents,” Nakamura added.

Geopolitically, the dual advances heighten competition between the U.S. and China. Both nations are racing to establish permanent bases on the Moon and Mars, and control of orbital manufacturing capabilities could determine who leads the next industrial revolution.

Challenges Ahead

Varda still faces regulatory hurdles: it must secure licenses from the FAA to return samples to Earth, and the FDA will need to approve any drugs produced in orbit. NASA’s NTP project, meanwhile, must overcome public skepticism about launching nuclear materials—even though the reactor would be dormant until it reaches space.

“The science is solid, but the politics and safety culture around nuclear space systems are always under a microscope,” said Zubrin. “That’s why the next two years are critical.”

Looking Forward

Both initiatives are moving from paper to hardware. Varda’s first production flight is scheduled for late 2025, while NASA expects to award the NTP construction contract within months. If successful, they will mark humanity’s first serious steps toward making space a permanent part of our industrial and logistical infrastructure.

As Nakamura put it: “These aren’t just experiments—they’re the foundations of a new economy beyond Earth.”